Immuron Travelan continued strong sales growth
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Immuron Limited reports continued strong sales growth for Travelan®, highlighting significant increases in revenue across various regions. The company noted that global sales for the December quarter reached a notable figure, reflecting substantial growth compared to previous periods. In Australia, sales also saw impressive growth, driven by expanded distribution and increased demand.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Immuron
- Immuron Announces Travelan Clinical Trial Update
- NMRC Reports Results for Campylobacter Clinical Study
- Trading Halt
- Immuron Plans Phase 2 Trial for IMM-529 following FDA review
- Appendix 4E and Preliminary Final Report
Later from Immuron
- IMC and Calmino to treat Irritable Bowel Syndrome (IBS)
- Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
- Immuron Travelan highest sales in history
- FY25 global sales exceed projection, up 49% on prior year
- Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron